Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Natural history, survival, and mortality
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Disease description

Natural history, survival, and mortality

1 evidence topic · 2 sources

Denmark: 10-year survival probability in the ISM group

“The 10-year survival probability was 86.8% (95%CI: 79.9–94.4%), 90.1% (95%CI: 87.8–92.5%), and 87.1% (95%CI: 83.6–90.8%) for CM, MIS, and ISM, respectively.” (opens the source at this quote in a new tab)